Efficacy and safety of etanercept in chronic immune-mediated disease
2014
Introduction: TNF-α inhibitors have demonstrated efficacy in large, randomized controlled clinical trials either as monotherapy or in combination with other anti-inflammatory or disease-modifying antirheumatic drugs in the treatment of chronic inflammatory immune-mediated diseases. Etanercept is a fusion protein that acts as a ‘decoy receptor’ for TNF-α. Areas covered: This paper evaluates the efficacy and safety of etanercept in patients with chronic inflammatory immune-mediated diseases. Expert opinion: Etanercept was first approved for the treatment of rheumatoid arthritis (RA) and subsequently of chronic plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and juvenile RA. Etanercept as other TNF-α inhibitors, particularly infliximab, may be administered off-label to treat other chronic inflammatory immune-mediated diseases such as systemic sclerosis, Behcet disease, systemic lupus erythematosus, polymyositis, dermatomyositis and mixed connective tissue disease. Early etanercept treatment pre...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
114
References
19
Citations
NaN
KQI